About Peptilogics
Peptilogics focuses on developing new peptide-based drugs to treat serious infections. The company uses machine learning to enhance its drug design process, allowing for more efficient and precise creation of therapeutics. Their main product, PLG0206, is currently being tested in clinical trials for treating prosthetic joint infections, which are difficult to manage and have few effective treatments available. What sets Peptilogics apart from other biotechnology firms is its unique combination of peptide biology and advanced technology in drug design. The goal of Peptilogics is to provide effective treatments for patients suffering from life-threatening diseases by advancing the field of peptide therapeutics.
Pittsburgh, PennsylvaniaHeadquarters
2013Year Founded
$44.1MTotal Funding
SERIES_BCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
11-50Employees
Benefits
Insurance, Health & Wellness - Dental Insurance, Disability Insurance, Flexible Spending Account (FSA), Health Insurance, Health Savings Account (HSA), Life Insurance, Mental Health Care, Supplemental Life Insurance, Vision Insurance
401K Plan
Family & Parenting - Dependent Care, Family Medical Leave, Maternity & Paternity Leave, Work From Home
Vacation & Time Off - Bereavement Leave, Paid Holidays, Sick Days, Vacation & Paid Time Off
Risks
High cost and complexity of clinical trials may strain financial resources.
Potential delays in regulatory approvals could affect commercialization timeline.
Emergence of new multi-drug resistant strains could challenge PLG0206 efficacy.
Differentiation
Peptilogics uses machine learning to explore new peptide therapeutic design spaces.
PLG0206 has FDA Orphan Drug and Qualified Infectious Disease Product Designations.
Peptilogics focuses on unmet medical needs like prosthetic joint infections.
Upsides
Peptide therapeutics market projected to reach $50 billion by 2027.
Positive Phase 1B trial data shows 93% success rate for PLG0206.
$3.3 million CARB-X funding supports fracture-related infection research.
Funding
Total raised$44.12 M
Latest valuation$177.00 M
StageSERIES_B
SERIES B
11/30/2020$35
$177.00 MEARLY VC
1/31/2020$3
$12.80 MSERIES A
8/31/2017$6
$27.50 M$1
$6.50 MCONVERTIBLE
8/31/2013N/A